What does evidence say about Rejuran and polynucleotide injections?
Polynucleotide injections have promising early aesthetic findings, but a 2024 systematic review found only nine low- or moderate-quality studies involving 219 patients; this is a lower-certainty evidence base, not proof of guaranteed regeneration.
Rejuran is a trademarked product family associated with polynucleotide treatment. Product formulations and terminology such as PN, PDRN and “salmon DNA” should not be treated as scientifically or regulatorily identical. AestheticClinic.my is an independent Malaysian publisher, not a clinic, so this page explains evidence and verification rather than recommending a provider.
Key takeaways
| Question | Answer |
|---|---|
| What is it? | Polynucleotide products contain nucleic-acid polymer fragments formulated for specific uses. Proposed aesthetic effects and tolerability depend on the exact composition, concentration, manufacturing, route and protocol. |
| Who may benefit? | Adults with a defined skin-quality goal who understand the evidence is emerging. |
| What does evidence show? | The systematic review reported promising changes in wrinkles, texture and elasticity in several studies, with generally mild transient effects and moderate-to-high satisfaction. |
| What is the main limitation? | Small lower-quality evidence base. |
| What should Malaysians verify? | The exact procedure, registered practitioner and relevant LCP scope, registered premises, and product or device where applicable. |
What are aesthetic polynucleotide injections?
Plain-language definition
Polynucleotide products contain nucleic-acid polymer fragments formulated for specific uses. Proposed aesthetic effects and tolerability depend on the exact composition, concentration, manufacturing, route and protocol.
Evidence from wound healing, laboratory studies or non-aesthetic PDRN use cannot be presented as direct proof of facial wrinkle, texture or elasticity outcomes. Rejuran also should not inherit evidence from every HA skin booster.
The words used in advertising can compress several different entities into one label. For Rejuran Malaysia, readers should separate the concern being assessed, the generic procedure or category, any named product or device, and the outcome actually measured. That distinction prevents evidence for one protocol from being presented as proof for every service using a similar name.
Why does assessment matter before choosing an option?
Assessment should define the target and measurement, disclose exact Rejuran product/formulation and manufacturer, review allergy/inflammatory history, fish-related product concerns where relevant, infection, prior injections, medicines and product status.
A useful assessment records the reader’s main concern, timeline, severity or pattern, previous treatment, current medicines, relevant medical history, skin or tissue characteristics, and tolerance for downtime and uncertainty. These factors can change whether Rejuran Malaysia is reasonable, whether a different option deserves priority, or whether treatment should be deferred.
Assessment also tests the goal. A request for complete, permanent or surgery-equivalent change may not match the evidence. The clinician should translate the goal into an observable outcome, explain how it will be documented, and discuss the option of no procedure alongside active alternatives.
What does current evidence show—and what remains uncertain?
The systematic review reported promising changes in wrinkles, texture and elasticity in several studies, with generally mild transient effects and moderate-to-high satisfaction. the systematic review of polynucleotides in aesthetic medicine.
The included evidence was small, heterogeneous and low to moderate quality, with variable treatment areas and techniques. Larger independent trials and standardised outcomes are needed. a clinical overview of injectable skin-booster categories.
Published averages do not predict an individual result. Study participants, devices or products, technique, treatment area, outcome scale and follow-up may differ from the proposed Malaysian service. Any estimate should therefore stay linked to the exact evidence base and be presented with the uncertainty that accompanies it. the NPRA product-search route.
Who may discuss a verified PN product?
- Adults with a defined skin-quality goal who understand the evidence is emerging.
- People who can identify the exact product and formulation rather than rely on “PN” alone.
- People who accept injections, temporary effects and uncertain magnitude/duration.
- People whose practitioner and Malaysian product route can be verified.
Who may need a different or more urgent assessment?
- Active infection/inflammation or open skin in the treatment area.
- Prior unexplained inflammatory reaction, unknown injectable or relevant allergy history.
- Expectation of permanent collagen regeneration, scar removal or disease treatment.
- A clinic that cannot provide exact product, batch, manufacturer or regulatory evidence.
What should happen from consultation to follow-up?
-
1. Define the concern and intended outcome
The consultation should identify what the reader wants to change, distinguish relevant patterns or diagnoses, document a baseline and agree on a realistic outcome. A marketing label is not a clinical assessment, and a package should not be selected before this step.
-
2. Verify the exact option
Record the generic procedure, named product or device, treatment area, parameters or dose basis, who will perform it and where. Check the practitioner’s registered identity and relevant LCP scope, the premises, and the product or device through the applicable official Malaysian source.
-
3. Discuss evidence, alternatives and consent
The consent discussion should place potential benefit beside important limitations, common adverse effects, uncommon serious complications, alternatives, expected recovery and the plan if the response is poor or a complication occurs. Questions should be answered before payment pressure or treatment.
-
4. Document treatment and reassess
If treatment proceeds, retain the date, exact item or technique, relevant parameters, batch where applicable, treatment area, aftercare and follow-up route. Reassessment should use comparable photographs or measures and should change or stop the plan when benefit, tolerability or safety does not justify continuing.
What are the potential benefits?
- Promising early findings for selected texture, wrinkle or elasticity measures.
- A distinct product page avoids conflating PN with all skin boosters.
- Product-specific documentation supports better adverse-event follow-up.
- A staged plan can stop when value or tolerability is inadequate.
What are the main limitations?
- Small lower-quality evidence base.
- Terminology and formulations vary.
- Mechanism claims may exceed demonstrated clinical outcomes.
- No guaranteed result, duration or universal protocol.
How does this compare with relevant alternatives?
| Option | May be discussed for | Important trade-off |
|---|---|---|
| Injectable HA skin booster | Selected hydration or radiance targets with product-specific evidence. | Different ingredient/evidence and injection risks. |
| Topical skincare | Barrier, hydration and photoprotection foundations. | No injection risk but more gradual/limited outcomes. |
| Resurfacing/energy procedure | Selected texture or scar targets. | Different mechanism, downtime and pigment/burn risks. |
No comparison table can choose an option for an individual. The useful question is whether the alternative targets the same problem with a better balance of evidence, expected magnitude, reversibility, downtime, cost basis and risk for that person.
What safety issues, contraindications or warning signs matter?
Pain, bumps, bruising, swelling, redness and tenderness can follow intradermal injections.
Infection, hypersensitivity, inflammatory reactions, nodules and delayed swelling need product-specific monitoring.
Product purity, storage, batch and exact formulation matter; marketing terminology cannot substitute for traceability.
Unexpected severe pain, colour/visual symptoms, fever, spreading redness, drainage or persistent nodules require prompt medical assessment.
What should happen after Rejuran treatment?
Keep the exact product/formulation, manufacturer, batch, amount/area and date. Ask how long injection bumps or swelling are expected.
Use clinician-directed gentle care and avoid unapproved massage or aggressive active skincare during initial recovery.
Assess results only after swelling resolves and against a defined target; do not repeat because of a package schedule without reassessment.
Malaysia Price Atlas
Want to compare current advertised prices?
The separate 2026 study publishes source-attributed Malaysian figures while keeping different products, devices, areas, units, sessions and package conditions distinct. It does not turn unlike offers into a false national average.
How should Malaysians verify the procedure, practitioner and premises?
Use the Ministry of Health Malaysia’s three-part sequence: verify the exact procedure, the registered practitioner and relevant LCP scope, and the registered premises. Where a medicinal product or medical device is involved, check the exact item through the appropriate NPRA or MDA source rather than relying on a brand logo or clinic screenshot.
Keep a dated record of the exact name, branch, product or device, quoted basis, consent discussion and aftercare route. An official registration check confirms only the field checked on that date; it does not guarantee individual suitability, clinical quality or outcome.
How can you test whether a proposed plan is specific enough?
A defensible plan for Rejuran Malaysia should be detailed enough for another qualified practitioner to understand what is being proposed and why. It should name the assessed concern, intended outcome, exact product, device or technique where relevant, treatment area, session or dose basis, alternatives, material risks, expected recovery, review point and the route for urgent help. Phrases such as “premium,” “medical grade,” “FDA approved,” “Korean technology” or “doctor designed” do not replace those facts.
Ask the practitioner to separate what is established, what is a reasonable clinical inference and what remains uncertain. If evidence comes from a different device, product, body area, population or protocol, that difference should be stated. Testimonials, immediate post-treatment photographs and mechanism diagrams can generate a hypothesis, but they cannot prove durable benefit or predict an individual result.
What should appear in the written consent and treatment record?
- The diagnosis or working assessment, baseline photographs or measures, and the specific outcome being pursued.
- The generic procedure plus exact brand, model, formulation, batch, parameters, dose or treatment area wherever applicable.
- Common effects, important uncommon harms, personal risk modifiers, alternatives—including no treatment—and realistic recovery.
- The practitioner, premises, price basis, included follow-up, cancellation terms and who will assess an unexpected reaction.
- A review point with stop, change or referral criteria rather than an automatic commitment to every session in a package.
How should results and value be judged?
Compare outcomes only after the expected short-term swelling, redness or other recovery has settled. Use the same lighting, angle, distance, expression and timing for photographs, or a relevant validated scale when available. A visible change may still be too small to justify cost, downtime or risk for that individual; satisfaction and clinical measurement are related but not identical outcomes.
For price, compare like with like: exact option, area, quantity or session basis, practitioner, consumables, medicines, review and complication support. A cheap package can be poor value when it is unsuitable, under-specified or difficult to stop. A higher price also does not prove expertise or outcome. Suitability, traceability, informed consent and a credible follow-up route remain the more useful quality signals.
Which related guides can help you decide?
Frequently asked questions
Is Rejuran the same as every PN or PDRN injection?
No. Product family, formulation, concentration and regulatory status must be identified exactly.
Is Rejuran a skin booster?
It may be marketed within that broad category, but its PN evidence should remain distinct from HA and other injectables.
Does Rejuran regenerate skin permanently?
Permanent regeneration is not established. Available clinical evidence is promising but small and lower certainty.
How many sessions are needed?
No universal course is established. Product evidence and clinical reassessment should guide further treatment.
Are the injection bumps normal?
Temporary bumps may occur, but the expected pattern and duration should be written; worsening or persistent symptoms need review.
How should Rejuran be verified in Malaysia?
Confirm exact product/formulation, manufacturer, batch and applicable Malaysian regulatory record, plus practitioner/LCP scope and premises.
What is the balanced conclusion?
Rejuran and aesthetic PN injections are emerging, product-specific treatments with promising but limited evidence. A responsible page separates PN from HA skin boosters and wound-healing claims, identifies the exact product, and keeps uncertainty, injection reactions and traceability central to consent.
References
- Polynucleotides in aesthetic medicine systematic review — study count, quality and outcomes
- Injectable skin-booster overview — category distinction
- NPRA product-search entrypoint — exact Malaysian product verification
- Malaysia Medical Device Register — applicable exact-item check
- MOH Malaysia 3P guidance — practitioner and premises verification
Research by: Synthevera Research Team. Evidence checked date: pending. Next review: pending. Keep this page draft and noindex until the recorded workflow reaches ready-to-publish.